相关实验视频

Updated: Jan 13, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

贾斯凯德 (非随机):一种用于异常性肺纤维化症的新型PDE4B抑制剂

Syeda Fadak Zahra Hujjat¹, Harshika Khaim Chandani², Devya Khaim Chandani³

¹Department of medicine, Allama Iqbal Medical College, Lahore, Pakistan.

Annals of medicine and surgery (2012)

|January 7, 2026

概括

贾斯凯德 (非随机),一种新的选择性固-4B抑制剂,有效地减缓了异常性肺纤维化 (IPF) 患者的肺功能下降,改善了耐受性. 这种新型药物为管理这种渐进的肺部疾病提供了有前途的治疗选择.

科学领域:

肺部病理学肺部病理学
药理学药理学是指药理学的学科.
纤维性疾病纤维性疾病

背景情况:

异形性肺纤维化 (IPF) 是一种渐进的肺病,治疗选择有限,当前疗法经常出现不良事件.
现有的治疗方法,如皮尔费尼和宁泰达尼布,常见的副作用导致停药,需要新药.
对于IPF来说,迫切需要更好地耐受,机械上不同的治疗方法.

研究的目的:

为了评估Jascayd (非随机囊) 的疗效和安全性,选择性固-4B抑制剂,在IPF的成年患者中.
与安慰剂相比,评估内兰多米拉斯特对肺功能下降的影响及其耐受性概况.
探索内兰多米拉斯作为IPF新疗法类的潜力.

主要方法:

第三期临床试验 (FIBRONEER-IPF和FIBRONEER-ILD) 涉及成人IPF患者.
施用Jascayd (非随机结合剂) 与安慰剂,并评估同时使用抗纤维素药物.
测量强迫生命能力 (FVC) 的年度下降率作为主要终点.
监测不良事件和停药率,以评估安全性.

主要成果:

在IPF患者中,与安慰剂相比,内兰多米拉斯显著降低了FVC下降的年率.
该药物表现出比非选择性PDE4抑制剂更好的耐受性,常见的副作用包括轻度腹,恶心和疲劳.
观察到治疗中断率很低,这表明患者的坚持良好.
长期延长数据显示持续的安全性和肺功能保护.

结论:

贾斯凯德 (非随机混合物) 是IPF的新疗法类别,具有抗炎和抗纤维作用.
它在减缓肺功能下降方面的有效性和有利的安全性,使其成为IPF治疗的宝贵补充.
涅拉多米拉斯提供了一个机械上独特的选择,可能使IPF的个性化,多途径治疗策略成为可能.

关键词:

杰斯卡伊德 (Jascayd) 是一个很棒的人.这是一种PDE4B抑制剂.抗纤维性治疗是一种抗纤维性治疗.异形性肺纤维化异形性肺纤维化没有随机混合.

更多相关视频

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...